Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.24.1.1.u2
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
3 Months Ended
Mar. 31, 2024
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended March 31, 

($ in thousands)

    

2024

    

2023

Qbrexza®

​

$

5,017

​

$

4,094

Accutane®

​

 

5,819

​

 

4,648

Amzeeq®

​

​

755

​

​

1,193

Zilxi®

​

​

273

​

​

314

Other / legacy

​

​

1,166

​

​

1,916

Total product revenues

​

$

13,030

​

$

12,165

Schedule of other revenue

​

​

​

​

​

​

​

​

​

    

Three-Month Periods Ended March 31,

($in thousands)

​

​

2024

​

​

2023

Other revenue

 

​

—

 

​

48

Total other revenue

​

$

—

​

$

48